Diana Wouters

3.5k total citations
86 papers, 2.6k citations indexed

About

Diana Wouters is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Diana Wouters has authored 86 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Immunology, 27 papers in Hematology and 22 papers in Genetics. Recurrent topics in Diana Wouters's work include Complement system in diseases (41 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Blood groups and transfusion (14 papers). Diana Wouters is often cited by papers focused on Complement system in diseases (41 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Blood groups and transfusion (14 papers). Diana Wouters collaborates with scholars based in Netherlands, United States and Switzerland. Diana Wouters's co-authors include Gertjan Wolbink, Lucien A. Aarden, Theo Rispens, Sacha Zeerleder, M. Hart, Pauline A. van Schouwenburg, Mieke C. Brouwer, Taco W. Kuijpers, S. Marieke van Ham and Richard B. Pouw and has published in prestigious journals such as Journal of Biological Chemistry, Blood and The Journal of Immunology.

In The Last Decade

Diana Wouters

86 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana Wouters Netherlands	28	1.4k	718	661	432	397	86	2.6k
Sylvia Miescher Switzerland	35	2.0k 1.4×	1.0k 1.4×	931 1.4×	467 1.1×	382 1.0×	102	3.6k
Samuele E. Burastero Italy	29	1.5k 1.1×	734 1.0×	396 0.6×	114 0.3×	268 0.7×	89	3.2k
Karen M. Haas United States	30	3.1k 2.2×	865 1.2×	793 1.2×	187 0.4×	355 0.9×	62	4.5k
Els R. de Groot Netherlands	13	1.2k 0.9×	603 0.8×	529 0.8×	176 0.4×	502 1.3×	17	2.4k
Annemieke M. H. Boots Netherlands	34	2.1k 1.5×	266 0.4×	822 1.2×	397 0.9×	1.2k 3.1×	100	3.9k
Michael J. Townsend United States	30	3.0k 2.1×	457 0.6×	771 1.2×	316 0.7×	1.2k 3.1×	53	4.6k
P E Lipsky United States	31	2.2k 1.5×	551 0.8×	841 1.3×	282 0.7×	269 0.7×	46	3.6k
Martin de Boer Netherlands	36	2.7k 1.8×	363 0.5×	1.4k 2.1×	417 1.0×	190 0.5×	106	4.2k
Fleur Bossi Italy	29	1.5k 1.0×	150 0.2×	600 0.9×	381 0.9×	495 1.2×	57	2.8k
Deborah K. Dunn‐Walters United Kingdom	40	3.0k 2.1×	811 1.1×	922 1.4×	189 0.4×	195 0.5×	102	4.6k

Countries citing papers authored by Diana Wouters

Since Specialization

Citations

This map shows the geographic impact of Diana Wouters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Wouters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Wouters more than expected).

Fields of papers citing papers by Diana Wouters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Wouters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Wouters. The network helps show where Diana Wouters may publish in the future.

Co-authorship network of co-authors of Diana Wouters

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Wouters. A scholar is included among the top collaborators of Diana Wouters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Wouters. Diana Wouters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baas, Inge O., Claudia C. Folman, Kyra A. Gelderman, et al.. (2023). C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia. Blood Advances. 7(13). 3128–3139. 7 indexed citations

Langereis, Jeroen D., Mieke C. Brouwer, Marlieke L.M. Jongsma, et al.. (2023). The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. Clinical & Translational Immunology. 12(1). e1436–e1436. 16 indexed citations

Mierlo, Gerard van, et al.. (2022). Plasma Exchange Therapy Using Solvent Detergent-Treated Plasma: An Observational Pilot Study on Complement, Neutrophil and Endothelial Cell Activation in a Case Series of Patients Suffering from Atypical Hemolytic Uremic Syndrome. Transfusion Medicine and Hemotherapy. 49(5). 288–297. 1 indexed citations

Georgiadou, Athina, Hyun Jae Lee, Michael Walther, et al.. (2019). Modelling pathogen load dynamics to elucidate mechanistic determinants of host–Plasmodium falciparum interactions. Nature Microbiology. 4(9). 1592–1602. 16 indexed citations

Pouw, Richard B., Mieke C. Brouwer, Marlon de Gast, et al.. (2019). Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Advances. 3(4). 621–632. 24 indexed citations

Jongsma, Marlieke L.M., et al.. (2018). CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research. Journal of Immunological Methods. 456. 15–22. 24 indexed citations

Pouw, Richard B., Mieke C. Brouwer, Anna E. van Beek, et al.. (2018). Complement Factor H-Related Protein 4A Is the Dominant Circulating Splice Variant of CFHR4. Frontiers in Immunology. 9. 729–729. 16 indexed citations

Beek, Anna E. van, Simone Kruithof, Ed Nieuwenhuys, et al.. (2018). Reference Intervals of Factor H and Factor H-Related Proteins in Healthy Children. Frontiers in Immunology. 9. 1727–1727. 15 indexed citations

Pouw, Richard B., Alberto López‐Lera, Santiago Rodrı́guez de Córdoba, et al.. (2018). High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B. Frontiers in Immunology. 9. 3073–3073. 28 indexed citations

10.

Beek, Anna E. van, Richard B. Pouw, Mieke C. Brouwer, et al.. (2017). Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human Plasma. Frontiers in Immunology. 8. 1328–1328. 33 indexed citations

11.

Engel, Ruchira, Irma Rensink, Dorina Roem, et al.. (2015). ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. Journal of Immunological Methods. 426. 114–119. 9 indexed citations

12.

Wouters, Diana, et al.. (2015). Lyse or not to lyse: Clinical significance of red blood cell autoantibodies. Blood Reviews. 29(6). 369–376. 25 indexed citations

13.

Schouwenburg, Pauline A. van, Simone Kruithof, M. Hart, et al.. (2014). Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies. Journal of Biological Chemistry. 289(50). 34482–34488. 54 indexed citations

14.

Ligtenberg, Antoon J.M., et al.. (2014). Complement activation by salivary agglutinin is secretor status dependent. Biological Chemistry. 396(1). 35–43. 10 indexed citations

15.

Boross, Péter, J.H. Marco Jansen, Jeanette H.W. Leusen, et al.. (2013). Inhibition of the Classical and Lectin Pathway of the Complement System by Recombinant LAIR-2. Journal of Innate Immunity. 6(3). 284–292. 20 indexed citations

16.

Mierlo, Geertje J. D. van, Nicole H.P. Cnubben, Diana Wouters, et al.. (2013). The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. Journal of Immunotoxicology. 11(1). 62–71. 21 indexed citations

17.

Hart, M., Diana Wouters, Gertjan Wolbink, et al.. (2011). Differential effect of drug interference in immunogenicity assays. Journal of Immunological Methods. 372(1-2). 196–203. 130 indexed citations

18.

Hamad, Osama A., Per H. Nilsson, Diana Wouters, et al.. (2010). Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1. The Journal of Immunology. 184(5). 2686–2692. 93 indexed citations

19.

Wouters, Diana, et al.. (2008). C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opinion on Biological Therapy. 8(8). 1225–1240. 35 indexed citations

20.

Wouters, Diana, M. Hart, Peter Bruins, et al.. (2005). Complexes between C1q and C3 or C4: Novel and specific markers for classical complement pathway activation. Journal of Immunological Methods. 298(1-2). 35–45. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact